289 related articles for article (PubMed ID: 35326475)
1. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.
Dorna D; Paluszczak J
Cells; 2022 Mar; 11(6):. PubMed ID: 35326475
[TBL] [Abstract][Full Text] [Related]
2. The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
Kleszcz R; Skalski M; Krajka-Kuźniak V; Paluszczak J
Eur J Pharm Sci; 2021 Nov; 166():105961. PubMed ID: 34363938
[TBL] [Abstract][Full Text] [Related]
3. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
4. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
[TBL] [Abstract][Full Text] [Related]
5. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.
Bais MV
J Dent Res; 2019 Mar; 98(3):268-276. PubMed ID: 30615537
[TBL] [Abstract][Full Text] [Related]
6. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
[TBL] [Abstract][Full Text] [Related]
7. Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.
Caeiro LD; Nakata Y; Borges RL; Zha M; Garcia-Martinez L; Bañuelos CP; Stransky S; Liu T; Chan HL; Brabson J; Domínguez D; Zhang Y; Lewis PW; Aznar Benitah S; Cimmino L; Bilbao D; Sidoli S; Wang Z; Verdun RE; Morey L
Genes Dev; 2024 Feb; 38(1-2):46-69. PubMed ID: 38286657
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone demethylases as a potential cancer therapy (Review).
Diao W; Zheng J; Li Y; Wang J; Xu S
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of histone lysine demethylases in prostate cancer.
Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of the Kdm genes in scallop Patinopecten yessoensis suggests involvement of histone demethylation in regulation of early development and gametogenesis.
Guo Z; Zhang L; Li Y; Wu S; Wang S; Zhang L; Bao Z
Comp Biochem Physiol B Biochem Mol Biol; 2020 Jun; 243-244():110434. PubMed ID: 32201355
[TBL] [Abstract][Full Text] [Related]
11. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
12. Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases.
Mao F; Shi YG
Adv Exp Med Biol; 2023; 1433():15-49. PubMed ID: 37751134
[TBL] [Abstract][Full Text] [Related]
13. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
14. Lysine Demethylation in Pathogenesis.
Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
[TBL] [Abstract][Full Text] [Related]
15. Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer.
Taylor-Papadimitriou J; Burchell JM
Cells; 2022 Mar; 11(7):. PubMed ID: 35406676
[TBL] [Abstract][Full Text] [Related]
16. LSD1 knockdown reveals novel histone lysine methylation in human breast cancer MCF-7 cells.
Jin Y; Huo B; Fu X; Cheng Z; Zhu J; Zhang Y; Hao T; Hu X
Biomed Pharmacother; 2017 Aug; 92():896-904. PubMed ID: 28601046
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone lysine demethylases - progress, challenges, and the future.
Thinnes CC; England KS; Kawamura A; Chowdhury R; Schofield CJ; Hopkinson RJ
Biochim Biophys Acta; 2014 Dec; 1839(12):1416-32. PubMed ID: 24859458
[TBL] [Abstract][Full Text] [Related]
18. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma.
Suchanti S; Stephen BJ; Awasthi S; Awasthi SK; Singh G; Singh A; Mishra R
Epigenomics; 2022 Mar; 14(5):279-293. PubMed ID: 35184601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
